Angiotensin Receptor-Neprilysin Inhibitors (ARNi) should be first line instead of ACE-I in Class II-III Chronic Heart Failure concluding discussion.
8 November 2019 (00:00 - 00:00)
Organised by:
5 More presentations in this session
Associate Professor D. Sim (Singapore, SG)
Professor J. Cleland (Glasgow, GB)
PCI should be first choice in end stage renal failure patients with multivessel or LM disease - Pro.
Professor M. Marwan (Erlangen, DE)
Associate Professor K. Sin (Singapore, SG)
Access the full session
The Event
ESC Asia with APSC & AFC
8 November - 10 November 2019
You may be interested in
Congress Session
